Yakov Pakhomov MD, PhD· @yakov_pakhomov · X·· 12 小时前评分60
正文 · 原文
@A_May_MD @deathtouch2k Same HR, different trials. S1801: phase 2, n=313, clinically detectable III–IV, EFS. INTerpath-001: phase 3, n=1137, resected IIB–IV incl. node-negative IIB/C where neoadjuvant isn't on the table, RFS. Cross-trial HR matching is a coincidence, not a finding. #ESMO26
热度 0 · 0 赞 · 0 回复 · 0 转发
会议摘要
来源:Yakov Pakhomov MD, PhD · x.com
